<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719338</url>
  </required_header>
  <id_info>
    <org_study_id>occult HCV in dialysis</org_study_id>
    <nct_id>NCT04719338</nct_id>
  </id_info>
  <brief_title>Occult HCV Infection After DAAD Treatment in Haemodialysis Patients</brief_title>
  <official_title>Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aims to evaluate the prevalence and predictors of Occult HCV among hemodialysis&#xD;
      (HD) patients who achieved 24 weeks sustained virological response (SVR) after treatment with&#xD;
      direct-acting antiviral agents (DAA) by detection of viral RNA in their peripheral blood&#xD;
      mononuclear cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In maintenance hemodialysis (MHD) patients, hepatitis C virus (HCV) infection is common and&#xD;
      may be associated with poor clinical outcomes. A lot of treatment options for HCV have&#xD;
      rapidly evolved over the past 5 years and various treatment choices for patients with&#xD;
      advanced CKD are currently available.1 The reappearance of HCV infection months or years&#xD;
      after sustained virologic response (SVR) may be due to the persistence of HCV in tissue cells&#xD;
      in spite of being undetected in serum. This situation is known as occult hepatitis C&#xD;
      infection (OCI).2 OCI is now a challenging entity in the field of post hepatitis management&#xD;
      and follow-up. OCI is described when HCV-RNA is detectable in liver and/or peripheral blood&#xD;
      mononuclear cells (PBMCs) in patients with undetectable serum HCV-RNA. To our knowledge ,&#xD;
      this is the first research to issue this problem in dialysis patients after treatment with&#xD;
      direct acting antiviral drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This research is a cross sectional study. Target population: thirty patients with end-stage renal disease (ESRD) receiving hemodialysis treatment from different dialysis centers in Alexandria will be enrolled in the study after achieving sustained virological response 24 weeks after the end of treatment with directly acting antiviral drugs (DAADs).will be screened for the presence of occult HCV infection.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occult HCV infection</measure>
    <time_frame>6 months</time_frame>
    <description>By assessing presence of HCV RNA in peripheral blood mononuclear cells (PBMCs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after confirmation of 24 weeks SVR after the end of treatment, we will collect samples of peripheral blood from each patient into EDTA tube and test for HCV RNA in peripheral blood mononuclear cells (PBMCs) .&#xD;
All patients included in this study will be subjected to full history taking and thorough clinical examination. The initial pre treatment data of the patients will be revised including body mass index (BMI), pre treatment status (naïve,experienced), pretreatment viral load by sensitive real-time HCV PCR technique, liver function tests, complete blood count, prothrombin time, international normalized ratio , Child-Pugh score, MELD score and FIB-4 score .</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .</intervention_name>
    <description>samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .</description>
    <arm_group_label>participants</arm_group_label>
    <other_name>occult HCV infection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients on regular hemodialysis treatment for more than 6 months.&#xD;
&#xD;
          -  Achieved sustained virological response 24 weeks after the end of treatment with&#xD;
             directly acting antiviral drugs (DAADs).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Mamdouh Elsayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Nephrology &amp; Internal Medicine, Faculty of medicine, Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shady F Abouelnaga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>fellow of Clinical and Chemical Pathology Department, Alexandria University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hend N Abd Elmoteleub, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lecturer of Hepatolgy and Internal Medicine Department, Faculty of Medicine, Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohamed mamdouh Elsayed, MD</last_name>
    <phone>+20 01068055103</phone>
    <email>dr_mohamedmamdouh87@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hend N Abd Elmoteleub, MD</last_name>
    <email>hendnaguib88@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamed Mamdouh Elsayed, MD</last_name>
      <email>dr_mohamedmamdouh87@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Maduell F, Belmar L, Ugalde J, Laguno M, Martínez-Rebollar M, Ojeda R, Arias M, Rodas L, Rossi F, Llovet LP, González LN, Mallolas J, Londoño MC. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. Gastroenterol Hepatol. 2019 Mar;42(3):164-170. doi: 10.1016/j.gastrohep.2018.07.015. Epub 2018 Oct 4. English, Spanish.</citation>
    <PMID>30293914</PMID>
  </reference>
  <reference>
    <citation>Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S, Shirali A, Mohammad-Alizadeh AH. Occult Hepatitis C Infection Among Hemodialysis Patients: A Prevalence Study. Ann Hepatol. 2017 Jul-Aug;16(4):510-513. doi: 10.5604/01.3001.0010.0277.</citation>
    <PMID>28611267</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <keyword>occult HCV, direct antiviral drugs, haemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

